An interventional study of Revascularization and Exercise therapy in Peripheral Arterial Disease and Cardiovascular Diseases, sponsored by Medical University Innsbruck. Recruiting at 1 site in Austria. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-13.
Sponsored by Medical University Innsbruck · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 74 studies in Peripheral Arterial Disease with a site in Austria — 7 open to participants now, 16 under way, 2 of them phase 3. Peripheral Arterial Disease · Austria.
Among the 74 studies in Peripheral Arterial Disease with a site in Austria, this one is the 38th largest by planned enrollment of the 58 interventional ones that give a count, is one of 10 that started in 2022, is one of 41 with no phase, reaches primary completion later than 5 of the 15 other live ones, and was the 69th registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →7 of the 74 studies in Peripheral Arterial Disease with a site in Austria are open now. Recruiting first, the newest first:
Medical University of Graz · Sites in Austria
Ages 18+
Biotronik AG · Sites in Austria, Belgium, France and 5 more countries
Ages 18+
CSL Behring · Sites in Austria, United States, Argentina and 32 more countries
Ages 18+
Medical University Innsbruck · Sites in Austria
Ages 18+
M.A. Med Alliance S.A. · Sites in Austria, United States, France and 7 more countries
Ages 18+
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
74 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 11 · Phase 4 4
First in 2004; this study’s year is marked. 10 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 170 across the 58 interventional studies, 376 across the 16 observational. Of the 49 that completed or were terminated, 20 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 74 have an industry lead sponsor. The 10 most frequent:
Medical University Innsbruck is the lead sponsor of 187 studies on the registry; 48 are open to participants now.
Medical University Innsbruck has 3 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Peripheral Arterial Disease with a site in Austria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04110327Micro Medical Solution, Inc.An All-Comers Observational Study of the MicroStent™ Peripheral Vascular Stent System in Subjects With Peripheral Arterial Disease | 2026-12-31 |
| NCT04912323R3 Vascular Inc.Study of the R3 Vascular Drug-Eluting Bioresorbable Scaffold in Treating Below the Knee Arterial Disease | 2026-12-31 |
| NCT07465627Medical University of GrazVessel Recoil in Specific CLTI Populations | 2027-06 |
| NCT05055297M.A. Med Alliance S.A.SELUTION4BTK Trial | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 74 studies in Peripheral Arterial Disease with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to investigate the effect of different treatment strategies on mitochondrial function and to correlate in-vitro results to findings from in-vivo measurements of mitochondrial function. The authors hypothesize that interventional revascularization and therefore the restoration of blood and oxygen supply is more relevant to mitochondrial function compared to the effect of exercise training.
Resulting from a chronic narrowing of arteries by atherosclerotic lesions, the leading clinical symptom of peripheral arterial disease (PAD), a walking induced pain, reduces quality of life of patients. Affected muscle regions are altered by a characterized myopathy and mitochondria are known to play a crucial role in this pathophysiological mechanism. There are different methodological approaches to investigate mitochondrial function in-vivo as well as in-vitro. Regarding our own preliminary data, mitochondria are known to recover after successful revascularization. The effect of different treatment strategies on mitochondrial function and the correlation of in-vitro to clinical more applicable in-vivo methods was understudied so far.
The overall aim of this study is to investigate the effect of different treatment strategies on mitochondrial function and to correlate in-vitro results to findings from in-vivo measurements of mitochondrial function. The authors hypothesize that interventional revascularization and therefore the restoration of blood and oxygen supply is more relevant to mitochondrial function compared to the effect of exercise training.
Patients with isolated pathologies of the superficial femoral artery and symptomatic PAD (Fontaine stage IIB) will be included and randomized to different treatment groups (conservative treatment versus interventional revascularization). Near-infrared refracted spectroscopy and the TIVITA ® hyperspectral camera will be used for in-vivo measurement of peripheral oxygen saturation and distal perfusion before and after an exercise. Muscle biopsies will be obtained from affected (gastrocnemius muscle) as well as from unaffected muscle (lateral vastus muscle) shortly before and 12 weeks after initiating treatment. Muscle samples will be investigated by measurement of CSA regarding mitochondrial content and HRR regarding mitochondrial respiration as well as for oxidative stress.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with intermittent claudication will receive conservative treatment with monitored exercise training for a total of 12 weeks (home-based training, minimum of three times a week, documented by using a diary with documentation of the type, the intensity and the duration of the training as well as by using a physical activity monitoring system (Move 4, Karlsruhe, Germany).
Other: Exercise therapy
will receive revascularization of the underlying atherosclerosis lesion of the superficial femoral artery. Depending on the exact morphology of the lesion, patients with short superficial femoral artery lesions (\<25 cm) will be subdivided into group 2A with endovascular treatment and patients with long superficial femoral artery lesions (\>25 cm) will be subdivided into group 2B with open surgical treatment
Procedure: Revascularization
Patients undergoing surgery for symptomatic varicose veins with excluded PAD will serve as a control group.
Depending on the exact morphology of the lesion, patients with short superficial femoral artery lesions (\<25 cm) will be subdivided into group 2A with endovascular treatment (percutaneous transluminal angioplasty with or without stenting) and patients with long superficial femoral artery lesions (\>25 cm) will be subdivided into group 2B with open surgical treatment (femoropopliteal bypass) .
Home-based monitored exercise training (walking), 3 times a week, monitored with log book and activity sensors.
Change in mitochondrial function after defined treatment
High-resolution respirometry of muscle biopsy sample
Time frame: After 12 weeks - compared to baseline at inclusion
Change of near infrared spectroscopy
Near infrared spectroscopy measurement of calf
Time frame: After 12 weeks - compared to baseline at inclusion
Change in flow mediated dilation of the brachial artery
Evaluation of endothelial dysfunction with ultrasound measurements of flow mediated dilation of the brachial artery.
Time frame: After 12 weeks - compared to baseline at inclusion
Change in standardized 6-minutes walking test
Evaluation of cardiovascular risk with measurement of maximal walking distance (meters) in 6 minutes.
Time frame: After 12 weeks - compared to baseline at inclusion
Change in ankle-brachial index
Evaluation of hemodynamic parameters (ankle-brachial index).
Time frame: After 12 weeks - compared to baseline at inclusion
Started Nov 2022 (actual). Primary completion is estimated for Dec 2024, 25 months after the start.
Of 261 non-industry interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's planned 25 months is below that.
Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University Innsbruck →